XenoPort planning follow-on

XenoPort Inc. (NASDAQ:XNPT) said late Wednesday it is planning a follow-on underwritten by Credit Suisse and RBC Capital. XenoPort was up $0.36 to $6.79.

Xenoport's Horizant gabapentin enacarbil is approved in the U.S. to treat restless legs syndrome and to manage postherpetic neuralgia. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has U.S. commercialization rights from Xenoport to the transported prodrug of gabapentin. ...